Group 1 pulmonary hypertension. Other specified pulmonary heart diseases
Conditions
Interventions
Intervention 1: Control group: Who will receive 10-20 mg of tadalafil and 125 mg of bosentan once or twice a day for four months. Intervention 2: Intervention group: Who will receive 10-20 mg of tadal
Treatment - Drugs
Control group: Who will receive 10-20 mg of tadalafil and 125 mg of bosentan once or twice a day for four months.
Intervention group: Who will receive 10-20 mg of tadalafil and 125 mg of bosentan once or twice a day in addition to 25 mg of spironolactone in addition to the standard treatment on a daily basis for
Sponsors
Vice Chancellor for Research, Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
12 Years to 76 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Patients with group 1 pulmonary hypertension; aged between 12 and 76 years. Exclusion criteria: Eisenmenger's syndrome; congenital diseases; scleroderma, thalassemia, systemic disease, cirrhosis, cor pulmonale, renal failure; frequent readmission and receiving inotropic therapy; left systolic dysfunction; mental disabilities; pulmonary disease of asthma; and unwillingness to follow up.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Systolic and diastolic function of the right ventricle. Timepoint: Before and four months after treatment. Method of measurement: Echo.;Clinical signs (blood pressure, heart rate, and oxygen saturation). Timepoint: Before and four months after treatment. Method of measurement: 6MWD test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum NT-ProBNP levels. Timepoint: Before and four months after treatment. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactEghane Mobaser
Mashhad University of Medical Sciences
Outcome results
None listed